Pharmicell파미셀
005690 · KOSPI · ₩005690 · 파미셀
₩9,800▲ ₩200 (2.08%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 44.4% | 44.4% | 32.9% | 27.6% | 39.6% | 46.1% |
| Operating margin | 32.4% | 30.1% | 7.2% | 2.3% | 14.7% | 15.0% |
| Net margin | 31.8% | 35.3% | 9.8% | 6.4% | 18.1% | 18.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +19.2% | +75.9% | +15.3% | −6.6% | +18.3% | — |
| Operating income growth | +28.5% | +636.8% | +259.2% | −85.4% | +16.6% | — |
| Net income growth | +7.4% | +536.3% | +77.0% | −67.1% | +14.4% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 32.4% | 38.3% | 7.6% | 4.5% | 15.0% | 14.6% |
| Return on assets | 25.4% | 31.4% | 6.6% | 3.5% | 10.4% | 9.9% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 28.4% | 26.9% | 14.8% | 15.1% | 41.4% | 46.6% |
| Net debt to equity | 7.0% | −12.0% | −9.2% | −14.0% | 2.9% | −14.0% |
| Current ratio | 714.8% | 484.8% | 628.2% | 556.0% | 218.5% | 266.7% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Pharmicell / 파미셀 / 005690 / KRX:005690
Source: KRX statistical information